Jun 4 |
ONVO Increases Cash and Improves Prospects
|
May 21 |
Organovo Data Presented at Digestive Disease Week (DDW2024) Demonstrating Potential for FXR314 as Combination Therapy with Tofacitinib for Inflammatory Bowel Disease
|
May 14 |
Organovo to Present Data on FXR314 at Digestive Diseases Week (DDW2024)
|
May 9 |
Organovo Holdings, Inc. Announces Pricing of $5.25 Million Public Offering
|
May 1 |
ONVO Announces Very Positive Phase 2 Results
|
Apr 15 |
Why Organovo Stock Is Up Today
|
Apr 15 |
Organovo reports positive mid-stage results for FXR314 in metabolic dysfunction-associated steatohepatitis
|
Apr 15 |
Organovo Announces Positive Phase 2 Results for FXR314 in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Showing Both Reduction in Liver Fat Content and Strong Safety and Tolerability Compared to Placebo
|
Apr 15 |
Why Medical Properties Trust Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket
|
Apr 12 |
Organovo files to sell common stock, warrants
|